Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-05-09 |
2024-03 |
-0.26 |
N/A |
N/A |
N/A |
2024-03-21 |
2023-12 |
-0.3 |
-0.32 |
-0.02 |
-6.67% |
2023-11-13 |
2023-09 |
-0.38 |
-0.35 |
0.03 |
7.89% |
2023-11-13 |
2023-09 |
-0.38 |
N/A |
N/A |
N/A |
2023-08-10 |
2023-06 |
-0.39 |
-0.37 |
0.02 |
5.13% |
2023-08-10 |
2023-06 |
-0.39 |
N/A |
N/A |
N/A |
Date |
Firm |
Action |
From |
To |
2023-08-13 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-06-19 |
Jefferies |
Downgrade |
Buy |
Hold |
2023-05-22 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-05-14 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-04-11 |
Oppenheimer |
Upgrade |
|
Outperform |
2023-03-29 |
HC Wainwright & Co. |
Upgrade |
|
Buy |
Date |
Name |
Relation |
Quantity |
Description |
2022-12-04 |
DAVID BHARUCHA |
Officer |
10.00K |
Purchase |
2020-07-28 |
FONDS DE SOLIDARITE DES TRAVAILLEURS DU |
Beneficial Owner of more than 10% of a Class of Security |
2.25M |
Sale |
2022-10-20 |
LIEBERT DEBRA KAY |
Director |
0.00 |
Purchase |
2020-08-25 |
MULLER LORENZ ANDREW |
Officer |
108.39K |
Conversion of Exercise of derivative security |
2019-12-19 |
OLIVETO JOSEPH GERARD |
Chief Executive Officer |
280.56K |
Conversion of Exercise of derivative security |
2022-10-19 |
PASTERNAK RICHARD C |
Director |
10.00K |
Purchase |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
RTW Investments LP |
3.26M |
9.28M |
9.75% |
2023-06-29 |
Blackrock Inc. |
2.65M |
7.56M |
7.94% |
2023-06-29 |
Goldman Sachs Group Inc |
2.56M |
7.28M |
7.65% |
2023-06-29 |
VR Adviser, LLC |
2.21M |
6.30M |
6.62% |
2023-06-29 |
Millennium Management Llc |
1.75M |
4.99M |
5.25% |
2023-06-29 |
Bleichroeder LP |
1.33M |
3.78M |
3.97% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-04-29 |
DFA U.S. Small Cap Series |
61.46K |
223.09K |
0.18% |
2023-04-29 |
DFA U.S. Micro Cap Series |
44.77K |
162.51K |
0.13% |
2023-07-30 |
SPDR (R) Idx Shares-SPDR (R) S&P (R) International Small Cap ETF |
21.61K |
69.80K |
0.06% |
2023-05-30 |
Fidelity NASDAQ Composite Index Fund |
17.58K |
69.25K |
0.05% |
2023-04-29 |
DFA U.S. Targeted Value Portfolio |
12.62K |
45.82K |
0.04% |
2023-04-29 |
DFA U.S. Core Equity 2 Portfolio |
6.89K |
24.99K |
0.02% |